Pfizer announces positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC: New York Friday, October 11, 2024, 09:00 Hrs [IST] Pf ...

According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...

(NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the ...

Kirkland & Ellis has successfully defended the validity of a pharmaceutical company's patent in London's High Court, ...

Investigators examined overall survival among real-world patients with metastatic prostate cancer (mCSPC) initiating enzalutamide vs apalutamide.

Pharma stock engaged in manufacturing and distributing of pharmaceutical products gained traction on Thursday’s trading ...

In a landmark study, Johnson & Johnson has announced that ERLEADA (apalutamide) significantly reduces the risk of death by 23 ...

Patients with metastatic castration-sensitive prostate cancer are recommended to be treated with enzalutamide tablets.

Wednesday, Johnson & Johnson (NYSE:JNJ) revealed results from a head-to-head study of Erleada (apalutamide) compared to ...

(RTTNews) - Johnson & Johnson (JNJ), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months ...

Based on real-world data, Johnson & Johnson (NYSE:JNJ) announced Wednesday its prostate cancer therapy Erleada (apalutamide) ...